These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23290835)

  • 1. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial.
    Grode L; Ganoza CA; Brohm C; Weiner J; Eisele B; Kaufmann SH
    Vaccine; 2013 Feb; 31(9):1340-8. PubMed ID: 23290835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa.
    Loxton AG; Knaul JK; Grode L; Gutschmidt A; Meller C; Eisele B; Johnstone H; van der Spuy G; Maertzdorf J; Kaufmann SHE; Hesseling AC; Walzl G; Cotton MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27974398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.
    Hoft DF; Blazevic A; Selimovic A; Turan A; Tennant J; Abate G; Fulkerson J; Zak DE; Walker R; McClain B; Sadoff J; Scott J; Shepherd B; Ishmukhamedov J; Hokey DA; Dheenadhayalan V; Shankar S; Amon L; Navarro G; Podyminogin R; Aderem A; Barker L; Brennan M; Wallis RS; Gershon AA; Gershon MD; Steinberg S
    EBioMedicine; 2016 May; 7():278-86. PubMed ID: 27322481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.
    Gengenbacher M; Nieuwenhuizen N; Vogelzang A; Liu H; Kaiser P; Schuerer S; Lazar D; Wagner I; Mollenkopf HJ; Kaufmann SH
    mBio; 2016 May; 7(3):. PubMed ID: 27222470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
    Cotton MF; Madhi SA; Luabeya AK; Tameris M; Hesseling AC; Shenje J; Schoeman E; Hatherill M; Desai S; Kapse D; Brückner S; Koen A; Jose L; Moultrie A; Bhikha S; Walzl G; Gutschmidt A; Kotze LA; Allies DL; Loxton AG; Shaligram U; Abraham M; Johnstone H; Grode L; Kaufmann SHE; Kulkarni PS
    Lancet Infect Dis; 2022 Oct; 22(10):1472-1483. PubMed ID: 35772447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
    von Reyn CF; Lahey T; Arbeit RD; Landry B; Kailani L; Adams LV; Haynes BC; Mackenzie T; Wieland-Alter W; Connor RI; Tvaroha S; Hokey DA; Ginsberg AM; Waddell R
    PLoS One; 2017; 12(5):e0175215. PubMed ID: 28498853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine.
    Fletcher HA
    mBio; 2016 Aug; 7(4):. PubMed ID: 27578760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.
    Hoft DF; Blazevic A; Abate G; Hanekom WA; Kaplan G; Soler JH; Weichold F; Geiter L; Sadoff JC; Horwitz MA
    J Infect Dis; 2008 Nov; 198(10):1491-501. PubMed ID: 18808333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guérin ΔureC::hly vaccine's superior protection against tuberculosis.
    Vogelzang A; Perdomo C; Zedler U; Kuhlmann S; Hurwitz R; Gengenbacher M; Kaufmann SH
    J Infect Dis; 2014 Dec; 210(12):1928-37. PubMed ID: 24943726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of Recombinant
    Figl J; Köhler H; Wedlich N; Liebler-Tenorio EM; Grode L; Parzmair G; Krishnamoorthy G; Nieuwenhuizen NE; Kaufmann SHE; Menge C
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis.
    Gengenbacher M; Kaiser P; Schuerer S; Lazar D; Kaufmann SH
    Microbes Infect; 2016 May; 18(5):364-8. PubMed ID: 26994939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.
    Nieuwenhuizen NE; Kulkarni PS; Shaligram U; Cotton MF; Rentsch CA; Eisele B; Grode L; Kaufmann SHE
    Front Immunol; 2017; 8():1147. PubMed ID: 28974949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
    Hawkridge T; Scriba TJ; Gelderbloem S; Smit E; Tameris M; Moyo S; Lang T; Veldsman A; Hatherill M; Merwe Lv; Fletcher HA; Mahomed H; Hill AV; Hanekom WA; Hussey GD; McShane H
    J Infect Dis; 2008 Aug; 198(4):544-52. PubMed ID: 18582195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments.
    Dietrich G; Viret JF; Hess J
    Vaccine; 2003 Jan; 21(7-8):667-70. PubMed ID: 12531337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
    Spertini F; Audran R; Chakour R; Karoui O; Steiner-Monard V; Thierry AC; Mayor CE; Rettby N; Jaton K; Vallotton L; Lazor-Blanchet C; Doce J; Puentes E; Marinova D; Aguilo N; Martin C
    Lancet Respir Med; 2015 Dec; 3(12):953-62. PubMed ID: 26598141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
    Blazevic A; Edwards RL; Xia M; Eickhoff CS; Hamzabegovic F; Meza KA; Ning H; Tennant J; Mosby KJ; Ritchie JC; Girmay T; Lai L; McCullough M; Beck A; Kelley C; Edupuganti S; Kabbani S; Buchanan W; Makhene MK; Voronca D; Cherikh S; Goll JB; Rouphael NG; Mulligan MJ; Hoft DF
    J Infect Dis; 2024 May; 229(5):1498-1508. PubMed ID: 38019956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe.
    Geldenhuys HD; Mearns H; Foster J; Saxon E; Kagina B; Saganic L; Jarrahian C; Tameris MD; Dintwe OB; Van Rooyen M; Luabeya KK; Hussey G; Scriba TJ; Hatherill M; Zehrung D
    Vaccine; 2015 Sep; 33(37):4719-26. PubMed ID: 25862299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
    Minhinnick A; Satti I; Harris S; Wilkie M; Sheehan S; Stockdale L; Manjaly Thomas ZR; Lopez-Ramon R; Poulton I; Lawrie A; Vermaak S; Le Vert A; Del Campo J; Hill F; Moss P; McShane H
    Vaccine; 2016 Mar; 34(11):1412-21. PubMed ID: 26854906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
    van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
    Front Immunol; 2018; 9():564. PubMed ID: 29632533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods.
    Rhodes SJ; Sarfas C; Knight GM; White A; Pathan AA; McShane H; Evans TG; Fletcher H; Sharpe S; White RG
    Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.